Vir Biotechnology: FDA Fast Track Status and New Clinical Data as Potential Price Drivers - Barclays Sets Target at $30!
Reading Time: 3 minutes
Vir Biotechnology (VIR) focuses on combating infectious diseases and cancer through the human immune system. Barclays analyst Etzer Darout confirmed a price target of $30, indicating significant upside potential given the current price. Recent developments, such as the FDA Fast Track designation for VIR-5500 and upcoming data on the Hepatitis Delta program, are shaping the operational business. Strategic Focus on Immunology and Oncology Vir Biotechnology (VIR) pursues a business model based on harnessing the human immune system to treat...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
